All In Biotech

Drug Trial Radar · NCT07136987

A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

A Randomized Controlled Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery (TB-MET-NAC)

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,104 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,104

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

Jan 2031

Study completion Jul 2031

Sponsor

Lead sponsor
Open Source Pharma FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Research in Tuberculosis, Chennai, India
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.

Conditions

  • Tuberculosis

Interventions

  • MetforminDrug

    Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment

  • N-Acetylcysteine (NAC) TreatmentDietary supplement

    N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment

  • Standard TB treatmentCombination product

    Standard TB treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1Time frame: month 18
  2. Favourable treatment outcomeTime frame: 18 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.